Countries that can offer lower costs during research and development while ensuring adequate protection of intellectual property and adherence to global regulatory standards are well positioned to attract the attention of large biopharmaceutical companies looking to outsource drug discovery and/or development. India is emerging as a powerhouse for several segments of the R&D value chain, including drug discovery, preclinical, and clinical development. China is also emerging as a competitive base for clinical development and manufacturing. In this chapter we comparatively analyze the life sciences industry in India and China and the drive toward outsourcing in these two countries. While commitment exists at the national, state, and local levels to enable the development of the life sciences industry and the outsourcing sector, several challenges exist and are analyzed in the chapter. Through the use of brief case studies we provide an overview of the activities of several multi-national companies located in India and China as well as the current state of affairs of contract research outsourcing in India and China.
About the Author:
Minna A. Damani
Mississauga, ON L5R 3K6 Canada
Minna A. Damani serves as Editor for CanBiotech’s BioMedical Outsourcing Report. She holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology, a Masters of Science in Biomedical Engineering from Brown University, and a Masters of Applied Science in the area of Management of Technology from the University of Waterloo. Her experience and expertise lie in the areas of biopharmaceutical commercialization, technology transfer, and partnership development. Her association with CanBiotech has enabled her to expand her expertise to the area of biopharmaceutical outsourcing and international business-to-business development.